Drugs / LEVOCARNITINE PROPIONATE
LEVOCARNITINE PROPIONATE
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02786069 | Jun → Nov 2015 | peripheral arterial disease | Lee's Pharmaceutical Limited | Completed | No outcome recorded |
| Phase 1 | NCT02786043 | Jun → Nov 2015 | peripheral arterial disease | Lee's Pharmaceutical Limited | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT01026857 | May 2006 → Apr 2009 | ulcerative colitis | sigma-tau i.f.r. S.p.A. | Completed | Met primary |
| Phase 34 trials · 1 missed | ||||||
| Phase 3 | NCT01567956 | Apr 2012 → Oct 2013 | ulcerative colitis | sigma-tau i.f.r. S.p.A. | Terminated | No outcome recorded |
| Phase 3 | NCT01538251 | Apr 2012 → Oct 2013 | ulcerative colitis | sigma-tau i.f.r. S.p.A. | Terminated | No outcome recorded |
| Phase 3 | NCT00809497 | May 2008 → Sep 2009 | peripheral arterial disease | Lee's Pharmaceutical Limited | Completed | No outcome recorded |
| Phase 3 | NCT00399919 | Apr 2006 → Mar 2008 | intermittent vascular claudication, peripheral arterial disease | Sigma-Tau Research, Inc. | Completed | Missed primary |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT04913805 Comparator | Oct 2021 → May 2027 expected | diastolic heart failure | University of Pennsylvania | Recruiting | No outcome recorded |
| Phase 4 | NCT01718288 Background | Nov 2006 → Mar 2011 | peripheral arterial disease | Fadoi Foundation, Italy | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2010-07-02 | Lee's Pharmaceutical Limited | Patients Enrollment completed in Clinical Study on Propionyl-L-Carnitine Tablets for treatment of Peripheral Arterial Diseases leespharm.com ↗ |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LEVOCARNITINE PROPIONATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1516469 ↗ |
| Known as | Dromos | ChEMBL registry synonym — accepted as the source's own label CHEMBL1516469 ↗ |
| Known as | Levocarnitine propionate hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1516469 ↗ |
| Known as | LEVOCARNITINE PROPIONATE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1516469 ↗ |
| Known as | NSC-759826 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1516469 ↗ |
| Known as | PLC | “Propionyl-L-carnitine Hydrochloride (PLC) is a molecule that has already been shown to reduce membrane lipid peroxidation in endothelial cells from bovine aorta and coronary...” NCT01538251 ↗3“This trial tested the hypothesis that propionyl-L-carnitine (PLC), in combination with monitored home-based exercise training, would improve treadmill peak walking time (PWT)...” PMID 20861750 ↗ Mar 2011 “AIM: To evaluate efficacy and safety of colon-release propionyl-L-carnitine (PLC) in patients with mild-to-moderate UC receiving stable oral aminosalicylate or thiopurine therapy.” PMID 21929562 ↗ Sep 2011 “Propionyl-L-Carnitine (PLC) 1000 mg twice daily” NCT04913805 ↗ |
| Known as | Propionyl-L-Carnitine | “standard heparin / low molecular weight heparin, hemorheological / vasodilators such as pentoxifylline / buflomedil, propionyl-L-carnitine, Defibrotide) but not prostanoids” NCT01718288 ↗ |
| Known as | Propionyl-l-carnitine chloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL1516469 ↗ |
| Known as | Propionyl-L-carnitine Hydrochloride | “Propionyl-L-carnitine Hydrochloride (PLC) is a molecule that has already been shown to reduce membrane lipid peroxidation in endothelial cells from bovine aorta and coronary...” NCT01538251 ↗ |
| Known as | ST 261 | “Given these properties of Propionyl-L-carnitine Hydrochloride (ST 261) and given the peroxidative damage suffered by colonocytes in UC together with their metabolic impairment,...” NCT01538251 ↗1“The trial foresees the administration of 2 different dosages of Propionyl-L-carnitine (ST261) colon release tablets, 1 g/die and 2 g/die.” NCT01026857 ↗ |
| Modality | Small molecule | — CHEMBL1516469 ↗ |
| Route | Oral | “oral administration of 2g daily” NCT00809497 ↗ |